Kintara Therapeutics, Inc. (NASDAQ:KTRA – Get Free Report) was up 16.2% on Thursday . The company traded as high as $0.11 and last traded at $0.10. Approximately 32,156,478 shares traded hands during mid-day trading, an increase of 171% from the average daily volume of 11,885,169 shares. The stock had previously closed at $0.09.
Kintara Therapeutics Stock Up 16.2 %
The firm has a market capitalization of $4.06 million, a price-to-earnings ratio of -0.02 and a beta of 0.59. The stock’s 50 day moving average price is $0.11 and its two-hundred day moving average price is $1.13.
Kintara Therapeutics (NASDAQ:KTRA – Get Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.24) earnings per share for the quarter. On average, equities analysts expect that Kintara Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.
Hedge Funds Weigh In On Kintara Therapeutics
About Kintara Therapeutics
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.
Further Reading
- Five stocks we like better than Kintara Therapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What Does a Stock Split Mean?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.